{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:30:51Z","timestamp":1760189451538},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T00:00:00Z","timestamp":1442793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00223-015-0061-y","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T02:07:38Z","timestamp":1442801258000},"page":"42-48","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta"],"prefix":"10.1007","volume":"98","author":[{"given":"Telma","family":"Palomo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara S. E.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda A.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Tom\u00e1s A.","family":"Carvalhaes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis H.","family":"Glorieux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marise","family":"Lazaretti-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,21]]},"reference":[{"key":"61_CR1","first-page":"1846","volume":"85","author":"H Plotkin","year":"2000","unstructured":"Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3\u00a0years of age. J Clin Endocrinol Metab 85:1846\u20131850","journal-title":"J Clin Endocrinol Metab"},{"key":"61_CR2","volume-title":"Osteogenesis imperfecta: a translational approach to brittle bone disease","author":"JR Shapiro","year":"2013","unstructured":"Shapiro JR, Byers PH, Glorieux FH, Sponseller PD (2013) Osteogenesis imperfecta: a translational approach to brittle bone disease. Elsevier, New York"},{"key":"61_CR3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947\u2013952","journal-title":"N Engl J Med"},{"key":"61_CR4","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377\u2013387","journal-title":"Cancer J"},{"key":"61_CR5","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","volume":"20","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS (2002) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719\u20133736","journal-title":"J Clin Oncol"},{"key":"61_CR6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/1078155206073520","volume":"12","author":"ML Lemos de","year":"2006","unstructured":"de Lemos ML, Taylor SC, Barnett JB, Hu F, Levin A, Moravan V, O\u2019Reilly SE (2006) Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database. J Oncol Pharm Pract 12:193\u2013199","journal-title":"J Oncol Pharm Pract"},{"key":"61_CR7","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","volume":"74","author":"MA Perazella","year":"2008","unstructured":"Perazella MA, Markowitz GS (2008) Bisphosphonate nephrotoxicity. Kidney Int 74:1385\u20131393","journal-title":"Kidney Int"},{"key":"61_CR8","first-page":"S37","volume":"5","author":"CJ Tyrrell","year":"1994","unstructured":"Tyrrell CJ (1994) Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multicenter phase II trial. Aredia Multinational Cooperative Group. Ann Oncol 5:S37\u2013S40","journal-title":"Ann Oncol"},{"key":"61_CR9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101\u2013116","journal-title":"J Med Genet"},{"key":"61_CR10","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1210\/jc.2002-021371","volume":"88","author":"F Rauch","year":"2003","unstructured":"Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH (2003) Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88:986\u2013992","journal-title":"J Clin Endocrinol Metab"},{"key":"61_CR11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1542\/peds.109.1.45","volume":"109","author":"CL Ogden","year":"2002","unstructured":"Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL (2002) Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45\u201360","journal-title":"Pediatrics"},{"key":"61_CR12","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1210\/jcem-70-5-1330","volume":"70","author":"C Glastre","year":"1990","unstructured":"Glastre C, Braillon P, David L, Cochat P, Meunier PJ, Delmas PD (1990) Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab 70:1330\u20131333","journal-title":"J Clin Endocrinol Metab"},{"key":"61_CR13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1148\/radiology.179.3.2027984","volume":"179","author":"RN Southard","year":"1991","unstructured":"Southard RN, Morris JD, Mahan JD, Hayes JR, Torch MA, Sommer A, Zipf WB (1991) Bone mass in healthy children: measurement with quantitative DXA. Radiology 179:735\u2013738","journal-title":"Radiology"},{"key":"61_CR14","volume-title":"Radiographic atlas of skeletal development of the hand and wrist","author":"WW Greulich","year":"1959","unstructured":"Greulich WW, Pyle SI (1959) Radiographic atlas of skeletal development of the hand and wrist. Stanford University Press, Stanford"},{"key":"61_CR15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","volume":"58","author":"GJ Schwartz","year":"1976","unstructured":"Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259\u2013263","journal-title":"Pediatrics"},{"key":"61_CR16","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","volume":"363","author":"F Rauch","year":"2004","unstructured":"Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363:1377\u20131385","journal-title":"Lancet"},{"key":"61_CR17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","volume":"86","author":"E Astrom","year":"2002","unstructured":"Astrom E, Soderhall S (2002) Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86:356\u2013364","journal-title":"Arch Dis Child"},{"key":"61_CR18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1515\/jpem-2012-0016","volume":"25","author":"ER Barros","year":"2012","unstructured":"Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M (2012) Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 25:485\u2013491","journal-title":"J Pediatr Endocrinol Metab"},{"key":"61_CR19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000323368","volume":"75","author":"I Vuorimies","year":"2011","unstructured":"Vuorimies I, Toiviainen-Salo S, Hero M, Makitie O (2011) Zoledronic acid treatment in children with osteogenesis imperfecta. Horm Res Paediatr 75:346\u2013353","journal-title":"Horm Res Paediatr"},{"key":"61_CR20","author":"T Palomo","year":"2015","unstructured":"Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH, Rauch F (2015) Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res. doi: 10.1002\/jbmr.2567","journal-title":"J Bone Miner Res"},{"key":"61_CR21","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","volume":"110","author":"F Rauch","year":"2002","unstructured":"Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293\u20131299","journal-title":"J Clin Invest"},{"key":"61_CR22","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bone.2006.04.004","volume":"39","author":"C Land","year":"2006","unstructured":"Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH (2006) Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 39:901\u2013906","journal-title":"Bone"},{"key":"61_CR23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0773.1997.tb01964.x","volume":"80","author":"JR Green","year":"1997","unstructured":"Green JR, Seltenmeyer Y, Jaeggi KA, Widler L (1997) Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 80:225\u2013230","journal-title":"Pharmacol Toxicol"},{"key":"61_CR24","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","volume":"12","author":"GS Markowitz","year":"2001","unstructured":"Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D\u2019Agati VD (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12:1164\u20131172","journal-title":"J Am Soc Nephrol"},{"key":"61_CR25","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ki.2008.193","volume":"74","author":"S Boonen","year":"2008","unstructured":"Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF, Miller PD (2008) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 74:641\u2013648","journal-title":"Kidney Int"},{"key":"61_CR26","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.bone.2011.09.035","volume":"49","author":"PD Miller","year":"2011","unstructured":"Miller PD, Ragi-Eis S, Mautalen C, Ramirez F, Jonkanski I (2011) Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease\u2013the DIVINE study. Bone 49:1317\u20131322","journal-title":"Bone"},{"key":"61_CR27","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20:2105\u20132115","journal-title":"J Bone Miner Res"},{"key":"61_CR28","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/jbmr.2058","volume":"28","author":"PD Miller","year":"2013","unstructured":"Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S (2013) Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res 28:2049\u20132059","journal-title":"J Bone Miner Res"},{"key":"61_CR29","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/ajcn\/37.3.478","volume":"37","author":"SB Heymsfield","year":"1983","unstructured":"Heymsfield SB, Arteaga C, McManus C, Smith J, Moffitt S (1983) Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr 37:478\u2013494","journal-title":"Am J Clin Nutr"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-015-0061-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-015-0061-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-015-0061-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T02:02:29Z","timestamp":1653184949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-015-0061-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,21]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["61"],"URL":"https:\/\/doi.org\/10.1007\/s00223-015-0061-y","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,21]]}}}